Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value

REFERENCES

1. 1.↵
   1. Chang CA,
   2. Gottlieb AB,
   3. Lizzul PF

   . Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011;7:588–98.

   OpenUrlPubMed
2. 2.↵
   1. Kurd SK,
   2. Gelfand JM

   . The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009;60:218–24.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Gladman DD,
   2. Antoni C,
   3. Mease P,
   4. Clegg DO,
   5. Nash P

   . Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Gottlieb A,
   2. Korman NJ,
   3. Gordon KB,
   4. Feldman SR,
   5. Lebwohl M,
   6. Koo JY,
   7. et al.

   Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851–64.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Stolwijk C,
   2. Boonen A,
   3. van Tubergen A,
   4. Reveille JD

   . Epidemiology of spondyloarthritis. Rheum Dis Clin North Am 2012;38:441–76.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Gottlieb AB,
   2. Mease PJ,
   3. Mark Jackson J,
   4. Eisen D,
   5. Amy Xia H,
   6. Asare C,
   7. et al.

   Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatolog Treat 2006;17:279–87.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Mease PJ,
   2. Menter MA

   . Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685–704.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Lundberg L,
   2. Johannesson M,
   3. Silverdahl M,
   4. Hermansson C,
   5. Lindberg M

   . Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000;80:430–4.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Gossec L,
   2. Smolen JS,
   3. Gaujoux-Viala C,
   4. Ash Z,
   5. Marzo-Ortega H,
   6. van der Heijde D,
   7. et al.

   European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Ash Z,
    2. Gaujoux-Viala C,
    3. Gossec L,
    4. Hensor EM,
    5. FitzGerald O,
    6. Winthrop K,
    7. et al.

    A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Costa L,
    2. Del Puente A,
    3. Peluso R,
    4. Tasso M,
    5. Caso P,
    6. Chimenti MS,
    7. et al.

    Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother 2017;18:1557–67.

    OpenUrl
12. 12.↵
    1. Bilal J,
    2. Riaz IB,
    3. Kamal MU,
    4. Elyan M,
    5. Sudano D,
    6. Khan MA

    . A systematic review and meta-analysis of efficacy and safety of novel interleukin inhibitors in the management of psoriatic arthritis. J Clin Rheumatol 2018;24:6–13.

    OpenUrl
13. 13.↵
    1. Coates LC,
    2. Helliwell PS

    . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–9.

    OpenUrlCrossRef
14. 14.↵
    1. Mease PJ,
    2. Heckaman M,
    3. Kary S,
    4. Kupper H

    . Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol 2013;40:647–52.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Perrotta FM,
    2. Marchesoni A,
    3. Lubrano E

    . Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 2016;43:350–5.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Lubrano E,
    2. De Socio A,
    3. Perrotta FM

    . Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: a cross-sectional analysis of a longitudinal cohort. J Rheumatol 2017;44:1159–64.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Wofford J,
    2. Menter A

    . Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2014;10:189–202.

    OpenUrl
18. 18.↵
    1. Gottlieb AB,
    2. Langley RG,
    3. Philipp S,
    4. Sigurgeirsson B,
    5. Blauvelt A,
    6. Martin R,
    7. et al.

    Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol 2015;14:821–33.

    OpenUrlPubMed
19. 19.↵
    1. Keating GM

    . Apremilast: a review in psoriasis and psoriatic arthritis. Drugs 2017;77:459–72.

    OpenUrl
20. 20.↵
    1. Coates LC,
    2. Navarro-Coy N,
    3. Brown SR,
    4. Brown S,
    5. McParland L,
    6. Collier H,
    7. et al.

    The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013;14:101.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Lubrano E,
    2. Mesina F,
    3. Caporali R

    . Clinical remission in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2018 Mar 16 (E-pub ahead of print).
22. 22.↵
    1. Schoels M,
    2. Aletaha D,
    3. Funovits J,
    4. Kavanaugh A,
    5. Baker D,
    6. Smolen JS

    . Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441–7.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Coates LC,
    2. Helliwell PS

    . Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 2016;43:371–5.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Smolen JS,
    2. Schöls M,
    3. Braun J,
    4. Dougados M,
    5. FitzGerald O,
    6. Gladman DD,
    7. et al.

    Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Sterry W,
    2. Ortonne JP,
    3. Kirkham B,
    4. Brocq O,
    5. Robertson D,
    6. Pedersen RD,
    7. et al.

    Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. WINPEPI (PEPI-for-Windows)

    . [Internet. Accessed August 22, 2018.] Available from: www.brixtonhealth.com/pepi4windows.html
27. 27.↵
    1. Strober B,
    2. Teller C,
    3. Yamauchi P,
    4. Miller JL,
    5. Hooper M,
    6. Yang YC,
    7. et al.

    Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322–30.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. van Mens LJJ,
    2. van de Sande MGH,
    3. van Kuijk AWR,
    4. Baeten D,
    5. Coates LC

    . Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 2018;77:251–7.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Gossec L,
    2. McGonagle D,
    3. Korotaeva T,
    4. Lubrano E,
    5. de Miguel E,
    6. Østergaard M,
    7. et al.

    Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol 2018;45:6–13.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Wervers K,
    2. Vis M,
    3. Tchetverikov I,
    4. Gerards AH,
    5. Kok MR,
    6. Appels CWY,
    7. et al.

    Burden of psoriatic arthritis in different definitions of disease activity: comparing Minimal Disease Activity and Disease Activity index for Psoriatic Arthritis. Arthritis Care Res 2018 Apr 2 (E-pub ahead of print).